Virus

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Wednesday, February 21, 2024
OTCQB, RSV, Virology, Nuclear magnetic resonance, Viral, Vaccine, Lower respiratory tract infection, University, COVID-19, Virus, Patient, Clinical trial, Molar, Carbohydrate, Mutation, Research

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Retrieved on: 
Wednesday, February 21, 2024
Biology, Pandemic, Vaccine, Antibody, Bacteria, Dyadic, Virus, Antigen, Patient, Partnership

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.

Key Points: 
  • JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.
  • Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR.
  • Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic.
  • Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

Retrieved on: 
Tuesday, February 20, 2024
Clinical research associate, Pomerantz, Viral, Court, Person, Prior, News, Complaint, District court, Ext, Virus, Patient, LLP, Action Replay, Research

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

Retrieved on: 
Tuesday, February 20, 2024
Viral, Court, Action Replay, News, Advertising, Complaint, District court, Virus, Patient, Defendant, Research, Security (finance)

If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.

Key Points: 
  • If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

CISO GLOBAL RECEIVES VALUATION OF MORE THAN $50 MILLION FOR INITIAL SUITE OF IP SOLUTIONS

Retrieved on: 
Tuesday, February 20, 2024
Cloud, Intel, Algorithm, DISC, AI, Intelligence, Artificial neural network, VPN, Virus, Automation, IP, Machine learning, Artificial intelligence, Medical device

Scottsdale, Ariz., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQCM: CISO), an industry leader as a managed cybersecurity and compliance provider, announces the independent valuation of its initial IP Solutions Portfolio by a global leader in valuation, corporate finance, and restructuring. This valuation includes four IP solutions – Skanda7 Breach Assessment Tool, CISO Edge Cloud Security Platform, CHECKLIGHT® Endpoint Security Monitoring, and DISC VPN. The new offerings are representative of the company’s push into delivering software-first solutions.

Key Points: 
  • (NASDAQCM: CISO), an industry leader as a managed cybersecurity and compliance provider, announces the independent valuation of its initial IP Solutions Portfolio by a global leader in valuation, corporate finance, and restructuring.
  • This valuation includes four IP solutions – Skanda7 Breach Assessment Tool, CISO Edge Cloud Security Platform, CHECKLIGHT® Endpoint Security Monitoring, and DISC VPN.
  • CISO Edge Cloud Security Platform – A cloud-first security solution designed to protect users from untrusted and malicious online threats.
  • CISO Global will continue to disrupt the status quo by delivering new IP already in development.”

Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision Antimicrobials

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, General Health, Health, Infectious Diseases, Genetics, Therapy, Campylobacter, Doctor of Philosophy, NIH, Collateral damage, News, Lysin, Bacteria, Ruminant, Environmental health, Virus, Genomics, Phase Genomics, Bill, Archaea, Melinda French Gates, AMR

Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.

Key Points: 
  • Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.
  • The foundation of this effort rests on Phase Genomics’ proprietary global phage atlas, developed with support from the Gates Foundation and the NIH.
  • Under this project, Phase Genomics will deploy its platform to develop antimicrobial agents that bypass resistance against Campylobacter infections and methanogenic archaea in ruminants that drive global methane emissions.
  • Follow Phase Genomics on X and LinkedIn for the latest news and information.

New frontier in fighting viruses: electromagnetic waves can render flu and COVID viruses inactive, with a success rate of over 90%. This is the “e4life” new smart prevention device.

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Health, Medical Devices, Infectious Diseases, Consumer Electronics, Health Technology, Technology, Mobile, Wireless, Transfer, Nature, Celio, H1N1, Field line, Siesta Key (TV series), Multimedia, Research, Aerosol, Translation, Animal, Hospital, Radiation, Wi-Fi, Biomedicine, University, COVID-19, ELT, Virus, Business, Lendlease, Electricity, Plasma protein binding, Human, Environment, Viral load, Vaccine

This started with the COVID-19 pandemic and continues today, with such products now accounting for 11% of the market.

Key Points: 
  • This started with the COVID-19 pandemic and continues today, with such products now accounting for 11% of the market.
  • This technology, patented in Italy, uses no chemical agents or filters, but instead transmits electromagnetic waves to render the viral load in aerosols inactive.
  • The unique e4shield technology subjects viruses to a precise oscillating electromagnetic field that resonates with the outer shell until it breaks.
  • Continuous scientific research will enable the devices to expand the number of types of pathogens that they can render inactive.

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Retrieved on: 
Monday, March 4, 2024
COVID-19, Research, Infectious Diseases, Stem Cells, Health, Pharmaceutical, Other Science, Science, Oncology, Nerve, SARS-CoV-2, Patent, TSOI, Business development, Virus, Patient, NK, Johns Hopkins University, Long, Cancer, Vaccine

Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19.
  • The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents:
    Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2.
  • Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5.
  • Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6.

Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health Technology, Health, Oncology, Neoplasm, Division, Senior, Investigational New Drug, CHLA, Regenerative medicine, Doctor of Philosophy, Multimedia, CIRM, Transplant, FDA, CBDI, TGFB, Sarcoma, Cell, Radiation, Interim, Survival rate, Bone marrow, Hematology, Virus, Tumor microenvironment, USC, Patient, Clinical trial, Survival, Research, Medicine, Vaccine

Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.

Key Points: 
  • Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.
  • (Photo: Business Wire)
    When cancer reoccurs in children and young adults with solid tumors such as sarcomas and neuroblastomas, there are few good treatment options.
  • This is why Children’s Hospital Los Angeles researchers focus on finding novel therapies using the patient’s own immune cells to treat childhood cancers.
  • In 2022, CIRM awarded $8 million to the Keck School of Medicine of USC and Children’s Hospital Los Angeles to establish a CIRM Alpha Clinic.

New Dassault Systèmes Virtual Twin Experience Helps Protect Vulnerable Patients and Educate Caregivers at Saint-Louis Hospital AP-HP in Paris

Retrieved on: 
Tuesday, February 27, 2024
Manufacturing, Biometrics, Other Health, Other Professional Services, Thought Leadership, Telemedicine, Virtual Medicine, Medical Devices, Hospitals, Electronic Design Automation, Professional Services, Data Management, Technology, Biotechnology, Health, Apps, Applications, Health Technology, Engineering, Training, Education, Hospital, Atmosphere, SIMULIA, PLM, Dassault Group, Multimedia, Physician, Dialysis, 3D, Product lifecycle, Immunodeficiency, Learning, Virus, Nursing, Control, Patient, Infection, Ventilation, Healthcare industry, Mask, Euronext Paris, Partnership

To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.

Key Points: 
  • To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.
  • Equipped with this information, Dassault Systèmes developed the augmented reality experience enabling the stakeholders to view the virtual simulations within the real-life setting.
  • “Dassault Systèmes had already worked on projects at other hospitals in Paris and understood our mission to offer the highest level of care.
  • “This incredibly innovative educational experience made our health professionals more aware of respiratory cross-transmission risks in the hospital.